Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination

• Published in: British journal of haematology Vol. 202; no. 6; pp. 1091 - 1103
• Main Authors: Pinder, Christopher L, Jankovic, Dylan, Fox, Thomas A, Kirkwood, Amy, Enfield, Louise, Alrubayyi, Aljawharah, Touizer, Emma, Ford, Rosemarie, Pocock, Rachael, Shin, Jin-Sup, Ziegler, Joseph, Thomson, Kirsty J, Ardeshna, Kirit M, Peppa, Dimitra, McCoy, Laura E, Morris, Emma C
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.09.2023; John Wiley and Sons Inc
• Subjects: Antibodies, Viral; Cell size; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Enzyme-linked immunosorbent assay; Flow cytometry; Hematologic Neoplasms - therapy; Hematology; Humans; Immunization; Immunoglobulin G; Malignancy; Original Paper; SARS-CoV-2; Seroconversion; Severe acute respiratory syndrome coronavirus 2; Vaccination; haematological malignancies; infection; antibodies; B cells; T cells; vaccines

Patients with haematological malignancies are more likely to have poor responses to vaccination. Here we provide detailed analysis of the humoral and cellular responses to COVID-19 vaccination in 69 patients with B-cell malignancies. Measurement of anti-spike IgG in serum demonstrated a low seroconv...